ARMP - Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024
PR Newswire
LOS ANGELES , July 10, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will deliver a presentation at Viruses of Microbes 2024, which is being held July 15-19, 2024 , in Cairns, Australia.
Details of the presentation are as follows:
Title: |
Advancing Bacteriophage Therapy from Discovery to Clinical Trials |
|
|
Session: |
Phage Therapy Session 2 – Clinical Application |
|
|
Presenter: |
Steven Branston, Australia Site Head |
|
|
Day: |
Thursday, July 18 |
|
|
Time: |
11:20am-11:40am AEST (9:20pm-9:40pm EDT on Wednesday, July 17) |
|
|
For more information: https://www.vom2024.org/ |
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa , Staphylococcus aureus , and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
ir@armatapharma.com
310-665-2928
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569
SOURCE Armata Pharmaceuticals, Inc.
News, Short Squeeze, Breakout and More Instantly...
Market Wire News is a media platform, the information on this page was provided by PR Newswire via Quote Media. Read our full disclaimer.